Abstracts tagged "autoimmune diseases"

Abstract Number: 1407 • 2017 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is an arthritis severity and joint damage gene recently discovered in rodent models of arthritis. Hip1 regulates fibroblast-like synoviocytes (FLS)…
Abstract Number: 2826 • 2017 ACR/ARHP Annual Meeting
Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc
Harm-Jan Westra¹, Marta Martinez-Bonet², Suna Onengut³, Annette Lee⁴, Yang Luo¹, Nikola Teslovich¹, Jane Worthington⁵, Javier Martín⁶, TWJ Huizinga⁷, Lars Klareskog⁸, Solbritt Rantapää Dahlqvist⁹, Wei-Min Chen³, Aaron Quinlan¹⁰, John Todd¹¹, Stephen Eyre⁵, Peter Nigrovic², Peter Gregersen⁴, Stephen Rich³ and Soumya Raychaudhuri¹², ¹Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Department of Public Health Sciences, University of Virginia, Charlottesville, VA, ⁴The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ⁵Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁹University of Umeå, Umeå, Sweden, ¹⁰Department of Human Genetics, University of Utah, Salt Lake City, UT, ¹¹JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ¹²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While genome-wide association studies have identified risk loci for rheumatoid arthritis and other autoimmune diseases, in very few instances have causal variants driving risk…
Abstract Number: 27 • 2017 ACR/ARHP Annual Meeting
Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab
Roberta Fenoglio¹, Laura Solfietti¹, Savino Sciascia² and Dario Roccatello¹, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Monoclonal antibodies (MoAbs) are highly successful in treating various immunological disorders. The development of anti-drug antibodies (ADA) against the therapeutic MoAb is relatively common.…
Abstract Number: 1466 • 2017 ACR/ARHP Annual Meeting
The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium
Irene Cecchi¹, Carlos Perez-Sanchez², Patricia Ruiz-Limon³, Ivan Arias de la Rosa³, Maria Carmen Abalos-Aguilera³, Yolanda Jiménez-Gómez², Rafaela Ortega-Castro², Eduardo Collantes-Estévez², Alejandro Escudero-Contreras³, Massimo Radin⁴, Nuria Barbarroja², Dario Roccatello⁵, Savino Sciascia⁶ and Chary Lopez-Pedrera⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain
Background/Purpose: Cardiovascular disease (CVD) constitutes a relevant cause of morbidity and mortality in Rheumatoid Arthritis (RA) patients. Rituximab (RTX) has been proved to be effective…
Abstract Number: 41 • 2017 ACR/ARHP Annual Meeting
A Fine Bioinformatical Analysis of Lymphocyte Distribution Predicts the Diagnosis of Systemic Autoimmune Diseases
Quentin Simon¹, Bénédicte Rouvière¹, Tifenn Martin¹, Lucas Le Lann¹, Alain Saraux¹, Valérie Devauchelle-Pensec¹, Concepcion Marañón², Nieves Varela Hernández², Aleksandra Dufour³, Carlo Chizzolini⁴, Ellen de Langhe⁵, Nuria Barbarroja⁶, Chary Lopez-Pedrera⁷, Velia Gerl⁸, Aurelie Degroof⁹, Julie Ducreux¹⁰, Elena Trombetta¹¹, Tianlu Li¹², Marta Alarcón-Riquelme¹³, Christophe Jamin¹ and Jacques-Olivier Pers¹, ¹U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ²GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain, ³Immunology & Allergy, University Hospital and School of Medicine, Geneva, Switzerland, ⁴University hospital of Geneva, Geneva, Switzerland, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ⁶Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain, ⁸Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁹Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹⁰Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Laboratorio di Analisi Chimico Cliniche e Microbiologia - Servizio di Citofluorimetria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ¹²Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ¹³GENYO. Center for Genomics and Oncological Research, Granada, Spain
Background/Purpose : We investigated 194 individuals with SADs (38 primary Sjögren’s syndrome (pSS), 47 rheumatoid arthritis (RA), 46 systemic lupus erythematosus (SLE), 42 systemic sclerosis…
Abstract Number: 1479 • 2017 ACR/ARHP Annual Meeting
Difference in Clinical Presentation between Female and Male Patients with Primary Sjogren’s Syndrome at Diagnosis and in Long-Term Follow-up
Jorge Ramírez¹, Marika Kvarnstrom², Susanna Brauner³, Chiara Baldini⁴, Per Eriksson⁵, Thomas Mandl⁶, Katrine Brække Norheim⁷, Svein Joar Johnsen⁸, Daniel S. Hammenfors^9,10, Malin V. Jonsson¹¹, Kathrine Skarstein^12,13, Johan G. Brun^9,10, Lars Rönnblom¹⁴, Helena Forsblad D’Elia¹⁵, Sara Magnusson Bucher¹⁶, Elke Theander¹⁷, Roald Omdal⁸, Roland Jonsson^9,10, Gunnel Nordmark¹⁸ and Marie Wahren-Herlenius¹⁹, ¹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Solna, Sweden, ²Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁴Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Division of Rheumatology, Department of Clinical Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ⁶Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, ⁷Department of Internal Medicine, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, Stavanger, Norway, ⁸Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, Stavanger, Norway, ⁹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, Bergen, Norway, ¹⁰Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ¹¹Section for Oral and Maxillofacial Radiology, Department of Clinical Dentistry, University of Bergen, Bergen, Norway, Bergen, Norway, ¹²Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, ¹³Department of Pathology, Haukeland University Hospital, Bergen, Bergen, Norway, ¹⁴Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ¹⁵Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden., Umeå, Sweden, ¹⁶Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, Örebro, Sweden, ¹⁷Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Malmö, Sweden, ¹⁸Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Despite men being less prone to develop autoimmune diseases, male sex has been associated with a more severe disease course in several systemic autoimmune…
Abstract Number: 164 • 2017 ACR/ARHP Annual Meeting
Association of Natural Killer Cell Ligand Polymorphism, HLA-C Asn80Lys, with the Development of Anti-SSA/Ro Associated Congenital Heart Block
Hannah C. Ainsworth¹, Miranda C Marion¹, Antonio Brucato², Nathalie Costedoat-Chalumeau³, Tiziana Bertero⁴, Rolando Cimaz⁵, Micaela Fredi⁶, Patrick M. Gaffney⁷, Jennifer A. Kelly⁷, Kateri Levesque⁸, Alice Maltret⁸, Nathalie Morel⁸, Véronique Ramoni⁹, Amelia Ruffatti¹⁰, Carl D Langefeld¹, Jill P. Buyon¹¹ and Robert M Clancy¹¹, ¹Wake Forest University, Winston Salem, NC, ²Ospedale Papa Giovanni XXIII, Bergamo, Italy, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Ospedale Mauriziano, Torino, Italy, ⁵Department of Paediatrics, University of Florence and Anna Meyer Children's Hospital, Florence, Italy, Florence, Italy, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Université Paris Descartes-Sorbonne Paris Cité, Paris, France, ⁹Ospedale Papa Giovanni XXIII of Bergamo, Policlinico San Matteo of Pavia, Bergamo, Pavia, Italy, ¹⁰Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, ¹¹NYU Langone Medical Center, New York, NY
Background/Purpose: Fetal exposure to maternal anti-SSA/Ro antibodies is necessary but insufficient for the development of congenital heart block (CHB), suggesting the potential of a fetal…
Abstract Number: 1741 • 2017 ACR/ARHP Annual Meeting
Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases
Francois-Xavier Danlos¹, Anne-Laure Voisin², Valérie Dyevre³, Jean-Marie Michot¹, Emilie Routier⁴, Laurent Taillade⁵, Stéphane Champiat¹, Sandrine Aspeslagh¹, Julien Haroche⁶, Laurence Albiges⁷, Christophe Massard¹, Nicolas Girard⁸, Stéphane Dalle⁹, Benjamin Besse⁷, Salim Laghouati², Jean-Charles Soria¹, Christine Mateus⁴, Caroline Robert⁴, Emilie Lanoy³, Aurélien Marabelle^1,10 and Olivier Lambotte¹¹, ¹Drug Development Department, Gustave Roussy Institut, Villejuif, France, ²Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, ³Service de biostatistique et d’épidémiologie, Gustave Roussy Institut, Villejuif, France, ⁴Department of dermatology, Gustave Roussy Institut, Villejuif, France, ⁵Department of medical oncology, Pitié Salpétrière Hospital, Paris, France, ⁶Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Department of medical oncology, Gustave Roussy Institut, Villejuif, France, ⁸8. Department of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France, ⁹Department of dermatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France, ¹⁰Immunotherapy program, Gustave Roussy Institut, Villejuif, France, ¹¹Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France
Background/Purpose: Patients with auto-immune or inflammatory diseases (AID) treated by immune check-points inhibitors (ICI) are intrinsically susceptible to develop immune related adverse events (irAE). We…
Abstract Number: 183 • 2017 ACR/ARHP Annual Meeting
Allele-Dependent Binding of a Viral Protein to Autoimmune Disease-Associated Genetic Variants
Matthew Weirauch¹, Daniel Miller², Leah C. Kottyan³, Ignacio Ibarra⁴, Arthur Lynch², Sayeed Syed⁵, Xiaoting Chen², Erin Zoller², Connor Schroeder², Josh Lee², Albert Magnusen⁶, Ally Yang⁷, Timothy R. Hughes⁷, Joo-Seop Park⁸, Charles Vinson⁵ and John B. Harley^2,9, ¹Center for Autoimmune Genomics and Etiology (CAGE) and Divisions of Biomedical Informatics and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany, ⁵NCI, Bethesda, MD, ⁶Center of Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷University of Toronto, Toronto, ON, Canada, ⁸Divisions of Urology and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Risk factors are known for many diseases, but the etiologies of most autoimmune diseases remain unknown and are idiopathic. Pathogenesis of disease likely involves…
Abstract Number: 1747 • 2017 ACR/ARHP Annual Meeting
Human C-C Chemokine Receptor-6 (CCR6)+ Th Memory Cells, Including Th17 and Th17.1 Cells, Change into Anti-Inflammatory Cells with Regulatory Capacity upon Exposure to Vitamin D
Wendy Dankers¹, Nadine Davelaar², Jan Piet van Hamburg³, Patrick Asmawidjaja², Hoyan Wen², Johannes van Leeuwen⁴, Edgar Colin⁵ and Erik Lubberts², ¹Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁴Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵ZGT Almelo, Deventer, Netherlands
Background/Purpose: Autoimmune diseases such as RA are driven by an aberrantly activated immune system and an imbalance between pro- and anti-inflammatory cells, resulting in tissue…
Abstract Number: 152 • 2017 Pediatric Rheumatology Symposium
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
TA Simon¹, A Baheti², N Ray², S Kelly¹ and Z Guo¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is…
Abstract Number: 147 • 2017 Pediatric Rheumatology Symposium
Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Lucas Picavet¹, Janneke Peeters², Sandra Coenen³, Arjan Boltjes⁴, Femke van Wijk⁵, Paul Coffer², Bas Vastert⁶ and Jorg van Loosdregt⁷, ¹Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory for Translational Immunity, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: For many autoimmune diseases, including Juvenile Idiopathic Arthritis (JIA), the molecular mechanisms remain elusive. JIA can be used as a model to study autoimmune…
Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Joan T. Merrill¹, Daniel J. Wallace², Stephen Wax³, Amy Kao⁴, Patricia Fraser⁴, Wai Chin⁴ and David A. Isenberg⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of California Los Angeles, Los Angeles, CA, ³EMD Serono, BIllerica, MA, ⁴EMD Serono, Billerica, MA, ⁵University College Hospital, London, London, United Kingdom

Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…
Abstract Number: 1428 • 2016 ACR/ARHP Annual Meeting
Patient Attitudes Towards Being Prescribed Biosimilars in Inflammatory Autoimmune Diseases in Germany
James Piercy¹, John Waller¹, Emma Sullivan¹, Christopher Black² and Sumesh Kachroo², ¹Adelphi Real World, Manchester, United Kingdom, ²CORE, Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Our aim is to address the lack of understanding surrounding patient attitudes to being prescribed biosimilars in the real world for Rheumatoid Arthritis (RA),…
Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting
Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Marius Albulescu¹, Jim Bush², Firas Almazedi², Ethan Grant³, Alex Godwood¹, Robert Miday⁴, Krista Arbaugh⁴, Lisa H. Butler¹, Michele Gunsior⁴, Jing Li⁵ and David Howe¹, ¹MedImmune, Cambridge, United Kingdom, ²Covance Clinical Research Unit, Leeds, United Kingdom, ³Translational Medicine, MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersburg, MD, ⁵MedImmune, Mountain View, CA
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].